Predictive Oncology Files 8-K on Material Agreement & Equity Sales

TL;DR

POAI filed an 8-K for a material agreement and equity sales on Aug 26.

AI Summary

Predictive Oncology Inc. entered into a material definitive agreement on August 26, 2025. The company also reported on unregistered sales of equity securities. The filing was made on September 2, 2025, and relates to events on August 26, 2025.

Why It Matters

This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks that require careful monitoring.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• August 26, 2025 (date) — Date of Earliest Event Reported
• September 2, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $0.01 — ch registered Common stock, par value $0.01 per share POAI NASDAQ Capital Market
• $0.76 — Common Stock ") at a purchase price of $0.76 per Share in a private placement. The o
• $413,093, b — any from the offering are approximately $413,093, before deducting offering expenses. The C

Filing Documents

• f8k_082625.htm (8-K) — 24KB
• 0001171843-25-005680.txt ( ) — 187KB
• poai-20250826_lab.xml (EX-101.LAB) — 33KB
• poai-20250826_pre.xml (EX-101.PRE) — 22KB
• poai-20250826.xsd (EX-101.SCH) — 3KB
• f8k_082625_htm.xml (XML) — 4KB

01. Entry into a Material Agreement

Item 1.01. Entry into a Material Agreement. On August 26, 2025, Predictive Oncology Inc., a Delaware corporation (" Predictive Oncology " or the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with an accredited investor (the " Investor ") for the sale by the Company of 543,544 shares (the " Shares ") of the Company's common stock, par value $0.01 per share (the " Common Stock ") at a purchase price of $0.76 per Share in a private placement. The offering closed on August 26, 2025. The Purchase Agreement contains customary representations and warranties and agreements of the Company and the investors and customary indemnification rights and obligations of the parties. Pursuant to the terms of the Purchase Agreement, the Company has agreed to certain restrictions on the issuance and sale of its Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement) following the closing of the offering through October 31, 2025, subject to certain exceptions contained therein. In addition, pursuant to the terms of the Purchase Agreement, the Company granted the Investor a 100% participation right in future offerings of equity securities by the Company through October 31, 2025. The gross proceeds to the Company from the offering are approximately $413,093, before deducting offering expenses. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. Pursuant to the terms of the SPA, the Company is required to prepare and file with the Securities and Exchange Commission a registration statement (registering the Shares for resale on or prior to the ninetieth (90 th ) day after the date of the Purchase Agreement. The foregoing description of the Purchase Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which will be filed as an exhibit to the Company's quarte

02

Item 3.02 Unregistered Sales of Equity Securities. The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. In the Purchase Agreement, the Investor represented to the Company, among other things, that it is an "accredited investor" (as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933, as amended (the "Securities Act")). The issuance of the Shares pursuant to the Purchase Agreement has been issued and sold by the Company to the Investor in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY INC. Date: September 2, 2025 By: /s/ Josh Blacher Name: Josh Blacher Title: Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR